Johnson & Johnson reports Q2 2024 results

RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)

RBC Capital analyst Shagun Singh reiterated an Outperform rating and $175.00 price target on Johnson & Johnson (NYSE: JNJ).

The analyst comments "JNJ's stock traded higher (+3.7%) post-Q2'24 beat. It maintained its FY24 adjusted operational sales growth outlook but lowered adjusted EPS to reflect M&A-related... More

Johnson & Johnson (JNJ) PT Raised to $160 at Stifel

Stifel analyst Rick Wise raised the price target on Johnson & Johnson (NYSE: JNJ) to $160.00 (from $155.00) while maintaining a Hold rating.

The analyst comments "Offsetting concerns about China and competitive pressures, JNJs robust Innovative Medicine (65.5% of sales, +8.8% y/y) performance reiterated a still-positive 2H24 growth... More

Johnson & Johnson (JNJ) gains as Q2 earnings, revenue beat estimates

Johnson & Johnson (NYSE: JNJ) reported a robust second quarter, with both earnings and revenue surpassing Wall Street estimates.

The healthcare giant posted adjusted earnings per share (EPS) of $2.82, exceeding analyst predictions by $0.10, and a revenue of $22.45 billion, also topping the consensus estimate of $22.34 billion.

This performance represents a 4.3% increase in reported sales growth, with an operational growth of 6.6%.

The company's stock responded positively to the news, with shares rising 2.1% as investors reacted favorably... More

Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.82, $0.10 better than the analyst estimate of $2.72. Revenue for the quarter came in at $22.45 billion versus the consensus estimate of $22.34 billion.

GUIDANCE:

Johnson & Johnson sees FY2024 EPS of $10.05, versus the consensus of... More